Skip to main content

Table 3 Results of constant-only threshold models

From: Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study

Minimum reduction in risk of:

Mean Threshold Estimate

Standard Error

95% CI

Tablet sample (n = 92)

 Hypertension from 25% needed to switch from tablets to IV (baseline difference = 14%)

7.07

0.97

(5.18–8.97)

 Decreased appetite from 16% needed to switch from tablets to IV (baseline difference = 13%)

7.94

0.87

(6.23–9.64)

 Hand-foot skin reaction from 45% needed to switch from tablets to IV (baseline difference = 45%)

9.84

1.28

(7.35–12.34)

 Diarrhea from 26% needed to switch from tablets to IV (baseline difference = 25%)

6.83

0.84

(5.17–8.48)

 Ascites from 11% needed to switch from tablets to IV (baseline difference = 11%)

10.07

1.22

(7.68–12.45)

 Proteinuria from 16% needed to switch from tablets to IV (baseline difference = 16%)

8.83

1.13

(6.62–11.05)

 Peripheral edema from 11% needed to switch from tablets to IV (baseline difference = 7%)

9.36

1.06

(7.28–11.44)

Intravenous sample (n = 58)

 Hypertension from 11% needed to keep IV instead of switching to tablets (baseline difference = 14%)

3.36

0.51

(2.35–4.36)

 Decreased appetite from 3% needed to keep IV instead of switching to tablets (baseline difference = 13%)

6.92

0.88

(5.19–8.65)

 Hand-foot skin reaction from 0% needed to keep IV instead of switching to tablets (baseline difference = 45%)

7.16

0.61

(5.96–8.36)

 Diarrhea from 1% needed to keep IV instead of switching to tablets (baseline difference = 25%)

6.66

0.58

(5.52–7.80)

 Maximum increase in risk of ascites from 0% needed to keep IV instead of switching to tablets (baseline difference = 11%)

8.51

0.70

(7.15–9.87)

 Maximum increase in risk of proteinuria from 0% needed to keep IV instead of switching to tablets (baseline difference = 16%)

8.35

0.81

(6.77–9.94)

 Maximum increase in risk of peripheral edema from 4% needed to keep IV instead of switching to tablets (baseline difference = 11%)

5.41

0.57

(4.28–6.54)

  1. CI confidence interval, IV intravenous
Back to article page